Medindia

X

Despite FDA's Letter to Merck Serono, Oral Cladribine is Still Expected to be the First Oral Disease-Modifying Therapy to Launch for Multiple Sclerosis in the United States

Tuesday, January 5, 2010 Drug News J E 4
Advertisement
Novartis/Mitsubishi Tanabe's FTY-720 Remains on Track for Launch in Early 2011, According to Findings from Decision Resources

Decision Resources

Decision Resources, Inc.

Christopher Comfort

Elizabeth Marshall

781-296-2597

781-296-2563

ccomfort@dresources.com  

emarshall@dresources.com

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Inverness Medical Innovations Enters Into Distribu...
S
Intuity Medical Closes $64 Million Series D Financ...